{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:23:08Z","timestamp":1788304988487,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/iae.0b013e31826d3a76","type":"journal-article","created":{"date-parts":[[2013,1,5]],"date-time":"2013-01-05T09:56:51Z","timestamp":1357379811000},"page":"613-620","source":"Crossref","is-referenced-by-count":14,"title":["APELIN IN EPIRETINAL FIBROVASCULAR MEMBRANES OF PATIENTS WITH RETINOPATHY OF PREMATURITY AND THE CHANGES AFTER INTRAVITREAL BEVACIZUMAB"],"prefix":"10.1097","volume":"33","author":[{"given":"Yan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-rong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity.","volume":"10","author":"Chen","year":"2007","journal-title":"Angiogenesis"},{"key":"R2-21-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.earlhumdev.2007.11.009","article-title":"Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control.","volume":"84","author":"Gilbert","year":"2008","journal-title":"Early Hum Dev"},{"key":"R3-21-20210130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1084-2756(03)00119-2","article-title":"Pathogenesis of retinopathy of prematurity.","volume":"8","author":"Smith","year":"2003","journal-title":"Semin Neonatol"},{"key":"R4-21-20210130","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.exer.2004.07.006","article-title":"Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy.","volume":"79","author":"Werdich","year":"2004","journal-title":"Exp Eye Res"},{"key":"R5-21-20210130","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00417-008-0865-9","article-title":". The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.","volume":"246","author":"Kwinta","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-21-20210130","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1523\/JNEUROSCI.15-07-04738.1995","article-title":". Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia.","volume":"15","author":"Stone","year":"1995","journal-title":"J Neurosci"},{"key":"R7-21-20210130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF03401566","article-title":". Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen.","volume":"1","author":"Shima","year":"1995","journal-title":"Mol Med"},{"key":"R8-21-20210130","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","article-title":"Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.","volume":"248","author":"Nazari","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R9-21-20210130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":". Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"key":"R10-21-20210130","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":". Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.","volume":"92","author":"Kusaka","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R11-21-20210130","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/IAE.0b013e318159ec6b","article-title":". Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.","volume":"28","author":"Quiroz-Mercado","year":"2008","journal-title":"Retina"},{"key":"R12-21-20210130","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IAE.0b013e3181644ad2","article-title":". Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity.","volume":"28","author":"Lalwani","year":"2008","journal-title":"Retina"},{"key":"R13-21-20210130","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R14-21-20210130","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3760\/cma.j.issn.0366-6999.2009.22.004","article-title":". Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study.","volume":"122","author":"Hou","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"R15-21-20210130","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/eye.2009.220","article-title":". Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion.","volume":"24","author":"Tao","year":"2010","journal-title":"Eye"},{"key":"R16-21-20210130","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.survophthal.2009.02.004","article-title":"Bevacizumab (Avastin) for the treatment of ocular disease.","volume":"54","author":"Gunther","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"R17-21-20210130","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1007\/s00125-008-0989-9","article-title":"Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy.","volume":"51","author":"Simo","year":"2008","journal-title":"Diabetologia"},{"key":"R18-21-20210130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1755-3768.2008.01353.x","article-title":". Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.","volume":"87","author":"Jiang","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R19-21-20210130","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.preteyeres.2008.09.002","article-title":"Vascular endothelial growth factor and diabetic complications.","volume":"27","author":"Wirostko","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"R20-21-20210130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.exer.2005.10.002","article-title":". Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: implications for structural differences in macular profiles.","volume":"82","author":"Patel","year":"2006","journal-title":"Exp Eye Res"},{"key":"R21-21-20210130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1006\/bbrc.1998.9489","article-title":". Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.","volume":"251","author":"Tatemoto","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-21-20210130","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.bcp.2007.12.015","article-title":"The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential.","volume":"75","author":"Japp","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"R23-21-20210130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2004.10.042","article-title":". Apelin is a novel angiogenic factor in retinal endothelial cells.","volume":"325","author":"Kasai","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"R24-21-20210130","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ydbio.2006.04.452","article-title":". Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo.","volume":"296","author":"Cox","year":"2006","journal-title":"Dev Biol"},{"key":"R25-21-20210130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ydbio.2007.03.004","article-title":". Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis.","volume":"305","author":"Kalin","year":"2007","journal-title":"Dev Biol"},{"key":"R26-21-20210130","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1038\/sj.onc.1210573","article-title":"Apelin is a potent activator of tumour neoangiogenesis.","volume":"26","author":"Sorli","year":"2007","journal-title":"Oncogene"},{"key":"R27-21-20210130","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1167\/iovs.09-4466","article-title":". Apelin in plasma and vitreous and in fibrovascular retinal membranes of patients with proliferative diabetic retinopathy.","volume":"51","author":"Tao","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-21-20210130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1051\/jbio\/2009021","article-title":". Apelin signalisation and vascular physiopathology in French.","volume":"203","author":"Masri","year":"2009","journal-title":"J Soc Biol"},{"key":"R30-21-20210130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0925-4773(01)00558-5","article-title":". Expression of the murine msrapj receptor and its ligand apelin is upregulated during formation of the retinal vessels.","volume":"110","author":"Saint-Geniez","year":"2002","journal-title":"Mech Dev"},{"key":"R31-21-20210130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1567-133X(03)00062-0","article-title":"The msrapj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature.","volume":"3","author":"Saint-Geniez","year":"2003","journal-title":"Gene Expr Patterns"},{"key":"R32-21-20210130","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1096\/fj.04-1930fje","article-title":". Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells.","volume":"18","author":"Masri","year":"2004","journal-title":"FASEB J"},{"key":"R33-21-20210130","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1096\/fj.06-7294com","article-title":". Hypoxia inducible factor regulates the cardiac expression and secretion of apelin.","volume":"21","author":"Ronkainen","year":"2007","journal-title":"FASEB J"},{"key":"R34-21-20210130","doi-asserted-by":"crossref","first-page":"E1590","DOI":"10.1152\/ajpendo.00490.2007","article-title":". HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes.","volume":"293","author":"Glassford","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R35-21-20210130","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1161\/CIRCRESAHA.108.179333","article-title":". Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis.","volume":"103","author":"Eyries","year":"2008","journal-title":"Circ Res"},{"key":"R36-21-20210130","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1749-6632.1999.tb09241.x","article-title":". Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1.","volume":"874","author":"Semenza","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R37-21-20210130","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/sj.emboj.7601982","article-title":". Spatial and temporal role of the apelinAPJ system in the caliber size regulation of blood vessels during angiogenesis.","volume":"27","author":"Kidoya","year":"2008","journal-title":"EMBO J"},{"key":"R38-21-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/IAE.0b013e3181e46ad8","article-title":"Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.","volume":"31","author":"Qian","year":"2011","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201303000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T09:57:38Z","timestamp":1714816658000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201303000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e31826d3a76","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}